Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376480 · ClinicalTrials.gov registry record · Phase 1
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00376480 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00376480, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methylprednisolone and antithymocyte globulin before transplant and peripheral blood cells that have been treated in the laboratory after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated peripheral blood cell infusion after donor stem cell transplant in treating patients with hematologic cancers or other diseases.
Interventions
- DRUG methylprednisolone
- DRUG fludarabine phosphate
- DRUG thiotepa
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL peripheral blood lymphocyte therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-06 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376480
The ClinicalTrials.gov registry entry for NCT00376480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which methylprednisolone is the first listed.
NCT00376480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376480 about?
NCT00376480 is a clinical study titled "Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant". RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a...
What is the current status of trial NCT00376480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-06. Estimated completion is 2018-05-16.
What interventions are being tested in trial NCT00376480?
The interventions under investigation include: methylprednisolone (DRUG), fludarabine phosphate (DRUG), thiotepa (DRUG), anti-thymocyte globulin (BIOLOGICAL), peripheral blood lymphocyte therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00376480?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.